All Type of News
Cosmetics of pharmaceutical companies have diversified distribution channels by expanding to pharmacies
For the last 6 months, launches of pharmacy cosmetic brands of pharmaceutical companies have continued, diversifying distribution channels.
That is, products of cosmeceutical, combining ‘cosmetic’ and ‘pharmaceutic...
Since the enforcement of the Patent Linkage System, approximately 1,600 patent trials were claimed
Since the enforcement of the Pharmaceutical Patent Linkage System on 15 March, it is known that approximately 1,600 cases of patent trials were claimed.
B2Pharm (CEO Hong-gi Lee), a pharmaceutical data analysis compa...
Ilsung Pharmaceuticals and Huons made the exclusive sale contract for the arteriosclerosis drug ‘Arigrel’Ilsung Pharmaceuticals (CEO Suk-geun Yoon) and Huons (CEO Jae-gab Jeon) held a signing ceremony of their exclusive sale contract for the arteriosclerosis treatment ‘Arigrel’ on ...
|
Will multinational pharmaceutical companies experience fluctuation in the sale rank?
It is known that sales of the top multinational pharmaceutical companies in Korea deceased a little last year, but their rank was not changed much.
According to recent audit reports turned by 31 multinational compani...
Xalkori is expected to exceed KRW 10 billion in the amount of claims for the first time of the year
The Pfizer Korea’s lung cancer treatment ‘Xalkori Cap(crizotinib)’ has been launched with the insurance benefit on the last 1st. It is expected that it will exceed KRW 14.5 billion in the first year’s claim amount due...
Will Pradaxa take the lead in the NOAC treatment market by the health insurance expansion?The insurance benefit range of the new oral anti-coagulant (NOAC) ‘Pradaxa(generic name: dabigatran)’ will be expanded from the 1st.
Through the expansion, the drug will not on...
|
The middle-grade pharmaceutical distribution company with the 3-year tradition, ‘Je Shin Pharm,’ turned in composition application
Je Shin Pharm, a pharmaceutical distribution company with the 30-year tradition, has applied composition due to experiencing pressure in its management.
It is confirmed on the 1st that Je Shin Pharm (CEO and Presiden...
The non-small cell lung cancer treatment is confirmed to be applied for the insurance benefit from the coming May
The non-small cell lung cancer treatment ‘Xalkori Cap’ will be applied for the National Health Insurance benefit from the coming May.
The Ministry of Health and Welfare announced on the 30th that it has decided on th...
‘Mirabegron’ is the most claimed substance after the enforcement of the Patent Linkage System
The substance, which has been claimed the most for patent trials after enforcement of the Pharmaceutical Patent Linkage System, was turned out to be the overactive bladder treatment, mirabegron.
CEO Hong-gi Lee of B2...
The psoriasis treatment market will launch a large number of generics
Competition in the psoriasis treatment market is expected to be fierce.
This is because a number of generic products are looking forward to being launched in the KRW 12 billion psoriasis market which has been exclusi...
